Kornimate/medical-research-clean huggingface dataset:
histopathological analysis of renal biopsies with dynamic full-field optical coherence tomography, a comparison to conventional histopathological findings for the diagnosis of either acute kidney injury or chronic kidney disease in routine practices (nephroct)

Conditions: Acute Kidney Injury; Chronic Kidney Diseases; Tomography, Optical Coherence

Summary: kidney biopsy play a key role for the investigation of either acute kidney injury or chronic kidney disease. despite possible complications due to the invasive nature of the biopsy, such procedure is still essential in a number of clinical situations to improve the diagnosis specificity of kidney disease, better inform about its prognosis and guide the management of a future treatment. pursuing the idea to improve both performance and rapidity associated with the histopathological analysis of kidney biopsy, with a possible recourse to artificial intelligence-based renal pathology, the present study intends to assess the impact of direct histopathological examination of kidney biopsy with dynamic full-field optical coherence tomography in routine practices for the diagnosis of either acute kidney injury or chronic kidney disease.


Eligibility criteria:
inclusion criteria: * patients \> 18 years of age with suspected acute kidney injury requiring biopsy in the nephrology department * patients \> 18 years of age with suspected chronic kidney disease requiring biopsy in the nephrology department exclusion criteria: * inability to perform dynamic full-field optical coherence tomography observation at the moment of kidney biopsy

Keywords: tomography, optical coherence chronic kidney diseases acute kidney injury kidney biopsy
study investigating the cardiotoxicity of anthracyclines in patients with diffuse large b-cell

Conditions: Lymphoma; Large B-Cell; Diffuse Large B-Cell

Summary: all patients enrolled in the study will have to be treated with a chemo immunotherapy scheme r-chop with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (r-comp; sec. 648 dm) administered every 21 days for 6 cycles. in unfavourable patients (stage ii-iv) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of r-chop.

the study was designed as a prospective observational multicenter study to evaluate the role of possible early markers of cardiotoxicity estimating an overall maximum risk equal to 20% of patients. the sample size, required to obtain an estimate of conventional anthracycline cardiotoxicity in the population, has been calculated with a confidence interval of 95% and a maximum acceptable error of ± 0.075. according to the conditions described above, the sample size of patients treated with conventional anthracycline results to be 124 patients. considering a 10-15% of not evaluable patients, the sample size is fixed at 150 patients treated with r-chop. the duration of the enrollment phase is defined in 2 years. with this sample size should be possible to assess the risk of cardiotoxicity related to predictors with a worst group frequency at least of 10%.

Eligibility criteria:
inclusion criteria: * histologically confirmed diffuse large b-cell lymphoma diagnosis * patient eligible to receive 6 cycles of r-chop or r-chop like chemotherapy at full doses * age ≥ 18 * stage i-iv * written informed consent * ecog performance status 0-3 * ventricular ejection fraction (vef) ≥40% * no previous treatment for lymphoma (except for rt-if) * negative β-hcg pregnancy test result at diagnosis for female of childbearing potential * use of acceptable method of contraception during the study and for 3 months after receiving the last dose of study drug for patients with childbearing potential * availability of the patient to be followed for all the phases of the chemotherapy treatment and for the subsequent follow-up exclusion criteria: * inability to schedule a treatment at full doses of chemoimmunotherapy r-chop or r-chop-like for different reasons * central nervous system involvement due to lymphoma * hiv * active cardiac pathology including heart failure, left ventricular dysfunction documented by a lvef \ moderate, ischemic heart disease (myocardial infarction or acute coronary syndrome for over 6 months, angina at rest or with mild efforts) * previous treatment for lymphoma * other malignancy in the 3 years prior to the diagnosis of lymphoma with exception of non-melanoma skin cancer or in situ carcinoma * any other co-existing medical condition that would preclude participation in the study (uncontrolled bacterial or viral or fungal infection) * pregnant, or lactating and breastfeeding female

Keywords: lymphoma large b-cell cardiotoxicity
recto-intercostal facial plane block in laparoscopic hiatus hernia repair

Conditions: Rectointercostal; Laparoscopic; Hiatus Hernia

Summary: the aim of this study is to evaluate the perioperative analgesic and intraoperative hemodynamic effects of ultrasound-guided bilateral recto-intercostal fascial plane block in patients undergoing laparoscopic hiatus hernia repair.

hiatus hernia is a prevalent condition in which the stomach or other abdominal organs protrude through the esophageal hiatus of the diaphragm into the thoracic cavity due to elevated pressure within the abdomen. laparoscopic hernioplasty of hiatal hernia has been confirmed effective and safe in recent years and performed more due to its mini-invasive nature and intraperitoneal view and operating angle. although patients having laparoscopic hiatus hernia repair experience less pain than open surgery, postoperative pain can still be significant and lead to associated postoperative issues. these issues can include respiratory and other complications, delay in discharge and adverse effects from increasing requirements of systemic analgesia such as opioid. an important consideration in the potential multitude of problems associated with increased opioid use is respiratory depression, sedation, constipation and the propensity for vomiting. postoperative vomiting can result in the repaired diaphragm enduring excessive pressure and subsequently early recurrence and failure of the procedure. recently, a novel block named "recto-intercostal fascial plane block" is performed between the recto abdominal muscle and costal cartilages of ribs 6-7 to block the anterior branches of the t6-t9 thoracic nerves, and laterally to the entire lower thorax. the investigators hypothesize that this block may provide perioperative analgesic benefits in patients undergoing laparoscopic hiatus hernia repair under general anesthesia.

Eligibility criteria:
inclusion criteria: * age from 18 to 65 years. * american society of anesthesiology (asa) physical status i-ii. * both sexes. * scheduled for elective elective laparoscopic hiatus hernia repair under general anesthesia. exclusion criteria: * patients with cardiovascular, pulmonary, or neurological diseases. * history of chronic pain or long-term or recent use of opioids. * coagulation disorders. * history of allergy to local anesthetic drugs. * history of previous abdominal surgery. * pregnancy.

Keywords: ultrasound rectointercostal laparoscopic hiatus hernia
iv acetaminophen for postoperative analgesia

Conditions: Postoperative Pain; Postoperative Nausea; Postoperative Vomiting

Summary: the purpose of this study is to evaluate the use of iv acetaminophen for postoperative pain management after laparoscopic cholecystectomy to determine if its use to supplement standard of care pain management decreases the incidence of post-operative nausea and vomiting.

the recent clinical development of an intravenous (iv) acetaminophen formulation for use in the us has important implications for the management of postoperative pain given its safety profile and suitability for use in the early phase of the postoperative period. in clinical studies a significant opioid-sparing effect has been documented with a substantial percentage of patients avoiding the need for opioid rescue medication altogether. this avoidance or delay in the use of opioids has been shown to reduce undesirable side effects. it is proposed that the use of iv acetaminophen in the post anesthesia care unit (pacu) for postoperative analgesia after laparoscopic cholecystectomy will result in decreased incidence of post operative nausea and vomiting (ponv) and decreased use of narcotics.

Eligibility criteria:
inclusion criteria: * subject is undergoing pre-scheduled laparoscopic cholecystectomy; * american society of anesthesiology patient classification status i-ii exclusion criteria: * regular preoperative use of or opioids, * subjects admitted after surgery for postoperative complications other than postoperative pain or ponv. * subjects converted to open laparoscopic cholecystectomy * known allergy/hypersensitivity to acetaminophen * use of opioids prior to commencement of the study (\<7 days) * patients with chronic pain conditions or disease requiring pain control * abnormal liver function * known or suspected alcohol, drug or opiate abuse or dependence * patients with a bmi of greater than 35 * other physical, mental or medical conditions that could effect participation. * abnormal renal function; serum creatinine\>2gm/dl

Keywords: iv acetaminophen laparoscopic cholecystectomy postoperative nausea postoperative vomiting
management of perforated peptic ulcer

Conditions: Perforated Peptic Ulcer

Summary: perforated peptic ulcer (ppu) is a common surgical emergency. exploratory laparotomy and repair with the omental patch are routine surgical intervention till now. in developing counties, laparoscopic repair is still not considered the gold standard in this emergency condition. this study was conducted to evaluate laparoscopic management of ppu in terms of peri-operative outcomes.

files of all patients admitted to our hospital with perforated peptic ulcer in the last 4 years and underwent operative management. demographic, clinical and perioperative outcomes will be collected tabulated and analyzed.

Eligibility criteria:
inclusion criteria: - all patients with perforated peptic ulcer admitted to our hospital in last 4 years and underwent surgical intervention. exclusion criteria: uncompleted patents files.

Keywords: peptic ulcer laparoscopic repair open repair graham patch
the efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on glp-1 receptor agonist and oad therapy

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe, oceania and the united states of america (usa). the aim of the trial is to investigate the efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on glucagon-like peptide-1 (glp-1) receptor agonist and oad therapy.


Eligibility criteria:
inclusion criteria: * subjects with type 2 diabetes mellitus * glycosylated haemoglobin (hba1c) 7.0-9.0% (53-75 mmol/mol) (both inclusive) * treatment with daily glp-1 receptor agonist at maximum dose according to local label (i.e. 1.8 mg once daily (od) victoza® (liraglutide) or 10 microgram twice daily (bid) byetta® (exenatide)) or documented maximum tolerated dose (i.e. 1.2 mg od victoza® (liraglutide) or 5 microgram bid byetta® (exenatide)) in combination with a stable daily dose of metformin (equal to or above 1500 mg or documented maximum tolerated dose) for 90 days or more prior to screening visit (visit 1) * bmi (body mass index) equal to or below 40 kg/m\^2 exclusion criteria: * any use of oral anti-diabetic drugs (oads) (except for metformin, pioglitazone and sulphonylurea) for 90 days or less prior to screening visit (visit 1) * use of any drug (except metformin,pioglitazone, sulphonylurea and glp-1 receptor agonist) which in the investigator's opinion could interfere with the blood glucose level (e.g. systemic corticosteroids) * treatment with any insulin regimen (short term treatment due to intercurrent illness including gestational diabetes is allowed at the discretion of the investigator) * screening calcitonin equal to or above 50 ng/l * personal or family history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia type 2 (men2) * cardiovascular disorders defined as: congestive heart failure (new york heart association (nyha) class iii-iv), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the past 52 weeks prior to screening visit (visit 1) and/or planned coronary, carotid or peripheral artery revascularisation procedures * proliferative retinopathy requiring acute treatment or maculopathy (macular oedema) according to the investigator's opinion * subjects with a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, endocrinological (except for the type 2 diabetes mellitus), neurological, genitourinary or haematological system that in the opinion of the investigator may confound the results of the trial or pose additional risk in administering trial products * history of chronic pancreatitis or idiopathic acute pancreatitis
spine ultrasound image study of spondylolisthesis patient

Conditions: Spondylolisthesis

Summary: this study is to evaluate the anatomical characteristics of spondylolisthesis patients using spine ultrasound imaging. the optimal angle of spinal needle insertion for spinal anesthesia in spondylolisthesis patients was compared to that of normal patients without abnormal spinal anatomy.


Eligibility criteria:
inclusion criteria: * adult patients scheduled for elective orthopedic surgery. * with asa physical status classification system i, ii, iii. exclusion criteria: * patients with communication difficulties. * patient who can not take a lateral decubitus position for spinal anesthesia. (e.g) fracture) * patients with a medical history of spinal surgery. * patients with significant spinal anatomical deformity any other than spondylolisthesis. (for spondylolisthesis patients group)

Keywords: optimal angle
effects of aspirin on uterine endometrial repair severe intrauterine adhesion

Conditions: Intrauterine Adhesion

Summary: this study aimed to investigate the effects of estrogen in combination with aspirin and intrauterine balloon on the uterine endometrial repair and reproductive prognosis in patients after surgery for severe intrauterine adhesion .

this cohort study was conducted to investigate whether aspirin could promote the endometrial growth and repair, reduce the recurrence of intrauterine adhesion and improve the menstruation and reproductive prognosis after surgery for severe intrauterine adhesion. menstruation was evaluated for the first time with a method similar to visual analogue scale (vas) in which the menstruation was assessed by the patients themselves with 0 as amenorrhea and 100 as normal menstruation. this evaluation avoids the vague terms (such as large or small menstrual blood volume) in previous evaluations and considers the individual difference in menstrual blood volume and different understanding about the menstrual blood volume. thus, this evaluation is easy to master, quantify and analyze.

Eligibility criteria:
inclusion criteria: * pre-operative adhesion score was ≥9 * the prior menstrual cycle was regular, and the sex hormone was normal * patients had fertility requirement * male semen examination showed normal; (5) there were no severe systemic diseases, and no contradictions to aspirin, estrogen and surgery exclusion criteria: * pre-operative adhesion score was \<9 * prior menstrual cycle was irregular and sex hormone was abnormal, or patients had endocrine factors that caused amenorrhea, menstrual reduction and infertility * patients had no fertility requirement * patients had male factor infertility * patients had contradictions to estrogen and aspirin such as cancers (breast cancer and endometrial cancer), thrombotic diseases, allergy to antipyretic analgesics, severe liver injury, hypoprothrombinemia, vitamin k deficiency, hemophilia, thrombocytopenia, gastric or duodenal ulcer and asthma.

Keywords: intrauterine balloon uterine endometrial repair intrauterine adhesion aspirin
achieving cardiovascular health equity in community mental health: optimizing implementation strategies

Conditions: Cardiovascular Risk Factors; Serious Mental Illness

Summary: in this trial, the investigators will examine the uptake of the evidenced-based ideal goals program, a heart disease risk reduction program, while testing different implementation strategies with our partners in michigan and maryland who serve persons with serious mental illness (smi).

in this trial, the investigators will work with michigan and maryland mental health programs to improve the uptake of the 18-month heart disease risk reduction program, ideal goals, to be delivered to persons with smi enrolled in their behavioral health homes.

Eligibility criteria:
community mental health program site staff participants: inclusion criteria 1. ages 18 and older 2. english speaking 3. agree to complete applicable data collection 4. agree to engage with the program according to their role (e.g., training, ideal goals program delivery).
study to assess change in disease symptoms in adult participants with moderate to severe psoriasis treated with subcutaneous risankizumab injection according to standard of care

Conditions: Psoriasis

Summary: psoriasis is a chronic inflammatory skin condition that is characterized by symptoms such as pain, itching and discomfort. this can have severe impact on the quality of life including depression, embarrassment, and social isolation. the objective of this study is to evaluate how effective risankizumab is in changing the disease symptoms in adult participants with moderate to severe psoriasis. risankizumab is an approved drug being developed for the treatment of psoriasis. adult participants who are prescribed risankizumab treatment according to the local label will be enrolled in this study. approximately 125 adult participants with moderate to severe psoriasis will be enrolled at multiple sites across israel. participants who are prescribed to receive subcutaneous risankizumab injection by their physician according to local label will be enrolled and will be followed for approximately 2 years. there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular visits during the study at a hospital or clinic. the effect of the treatment will be checked by medical assessments, checking for side effects, patient charts, questionnaires, and remote monitoring device (patch sensor).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of moderate to severe psoriasis. * prescribed risankizumab as the standard treatment for psoriasis, according to the local label. the decision to prescribe risankizumab will be made solely by the physician, based on his clinical judgment, and is done prior to any decision to approach the participant to participate in this study. * willing to be involved in the study, to sign an informed consent form and complete study questionnaires. * participants participating in digital component: pruritus numeric rating scale (pnrs) score \>=4 at baseline. exclusion criteria: * participants participating in a concurrent clinical interventional study or within 30 days. * participants treated with risankizumab prior to baseline visit.

Keywords: psoriasis risankizumab skyrizi primma
deep learning model for diagnosis and contour of cervical lymph node for nasopharyngeal carcinoma

Conditions: Deep Learning Model

Summary: the diagnosis of cervical lymph node in nasopharyngeal carcinoma is difficult. magnetic resonance imaging based deep learning model may be a noninvasive and rapid diagnostic method for cervical lymph node. thus, the investigators aimed to develop and externally validate a deep learning model to assist in the diagnosis and localization of metastatic lymph nodes in nasopharyngeal carcinoma.


Eligibility criteria:
inclusion criteria: * pathological diagnosis of nasopharyngeal carcinoma; cervival lymph nodes confirmed by pathology exclusion criteria: * a history of cancer
clinical outcome of patients with covid-19 pneumonia treated with corticosteroids and colchicine

Conditions: Covid-19

Summary: cross sectional study of 301 adult patients with covid-19 pneumonia treated with corticosteroid and/or colchicine

a cross sectional study of 301 adult patients with covid-19 pneumonia confirmed by real-time polymerase chain reaction for sars-cov2 (rt-pcr sars-cov2), berlin protocol, who required hospitalization in three hospitals in antioquia, colombia. patients were treated according to the institutional protocol (from march 20, 2020 to june 30, 2020) with corticosteroid if the patient required supplemental oxygen. from july 1, 2020, the management protocol changed with the addition of colchicine to all patients admitted to the institutions. the treatment was supervised and monitored by the same specialist in infectology of the institutions. we describe the clinical manifestations and outcomes of the patients who received these treatments. the patient's information was analyzed according to the outcome of interest (alive/dead) with univariate, bivariate, and multivariate measures to adjust the variables that presented statistical association.

Eligibility criteria:
inclusion criteria: * the included patients were older than 18 years hospitalized for covid-19 pneumonia, confirmed positive by real-time reverse transcription polymerase chain reaction for sars-cov2 (rt-pcr sars-cov2) by berlin protocol. the samples were taken from a nasopharyngeal swab. * the patients should also have radiological confirmation of pneumonia, mostly chest tomography or chest x-rays, to support the diagnosis of covid-19 pneumonia. exclusion criteria:

Keywords: dexamethasone corticosteroid covid-19 pneumonia colchicine clinical outcome
ingestion of lipids and changes in cerebral blood flow of people with obesity

Conditions: Obesity

Summary: this study aims to determine changes in cerebral blood flow of people with obesity after the ingestion of fat.


Eligibility criteria:
inclusion criteria: * live in ribeirão preto, são paulo - brazil. * regular menses. * weight inferior than 120 kg and body mass index (bmi) between 30 and 40 kg/m2, for the group with obesity. * bmi between 18,5 and 24,9 kg/m2, for the group without obesity. exclusion criteria: * high blood pressure, diabetes, glucose intolerance or impaired fasting glycemia, metabolic syndrome, hypothyroidism and any kidney, liver, heart or neurologic disease. * psychiatric disorders, alcoholism, smoking or illicit drug abuse. * pregnancy or desire to be pregnant * use of medications, excluding contraceptives. * contraindication for magnetic resonance imaging. * be in treatment for obesity.

Keywords: obesity lipids single photon emission computed tomography functional neuroimaging